$3.07
0.33% today
Nasdaq, Feb 28, 04:50 pm CET
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

CureVac N.V. Stock price

$3.06
-0.72 19.05% 1M
-0.22 6.71% 6M
-0.35 10.26% YTD
-0.52 14.53% 1Y
-13.76 81.81% 3Y
-52.84 94.53% 5Y
-52.84 94.53% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.15 4.52%
ISIN
NL0015436031
Symbol
CVAC
Sector
Industry

Key metrics

Market capitalization $686.38m
Enterprise Value $116.37m
P/E (TTM) P/E ratio 5.57
EV/FCF (TTM) EV/FCF 1.03
EV/Sales (TTM) EV/Sales 0.20
P/S ratio (TTM) P/S ratio 1.15
P/B ratio (TTM) P/B ratio 0.85
Revenue growth (TTM) Revenue growth 1,202.27%
Revenue (TTM) Revenue $595.81m
EBIT (operating result TTM) EBIT $179.96m
Free Cash Flow (TTM) Free Cash Flow $113.23m
Cash position $614.79m
EPS (TTM) EPS $0.55
P/E forward 3.57
P/S forward 1.27
EV/Sales forward 0.22
Short interest 9.07%
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a CureVac N.V. forecast:

3x Buy
50%
2x Hold
33%
1x Sell
17%

Analyst Opinions

6 Analysts have issued a CureVac N.V. forecast:

Buy
50%
Hold
33%
Sell
17%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
596 596
1,202% 1,202%
100%
- Direct Costs 192 192
8% 8%
32%
404 404
406% 406%
68%
- Selling and Administrative Expenses 52 52
20% 20%
9%
- Research and Development Expense 145 145
32% 32%
24%
206 206
167% 167%
35%
- Depreciation and Amortization 26 26
15% 15%
4%
EBIT (Operating Income) EBIT 180 180
154% 154%
30%
Net Profit 124 124
139% 139%
21%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
Accesswire
10 days ago
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of the broadest intellectual property portfolios in mRNA technology TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / February 18, 2025 / CureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical compa...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 1,172
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today